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Effectiveness of azacitidine in unselected high-risk
myelodysplastic syndromes: results from the Spanish registry
T Bernal1, P Martínez-Camblor1,2, J Sánchez-García3, R de Paz4, E Luño1, B Nomdedeu5, MT Ardanaz6, C Pedro7, ML Amigo8, B Xicoy9,
C del Cañizo10, M Tormo11, J Bargay12, D Valcárcel13, S Brunet14, L Benlloch15 and G Sanz16 on behalf of The Spanish Group on
Myelodysplastic Syndromes and PETHEMA Foundation, Spanish Society of Hematology
The beneﬁt of azacitidine treatment in survival of high-risk myelodysplastic syndromes (MDS) patients compared with conventional
care treatment (CCT) has not been established outside clinical trials. To assess its effectiveness, we compared overall survival (OS)
between azacitidine and conventional treatment (CCT) in high-risk MDS patients, excluding those undergoing stem cell
transplantation, submitted to the Spanish MDS registry from 2000 to 2013. Several Cox regression and competing risk models,
considering azacitidine as a time-dependent covariate, were used to assess survival and acute myeloblastic leukemia (AML)
progression. Among 821 patients included, 251 received azacitidine. Median survival was 13.4 (11.8–16) months for azacitidine-
treated patients and 12.2 (11–14.1) for patients under CCT (P= 0.41). In a multivariate model, age, International prognostic scoring
system and lactate dehydrogenase were predictors of OS whereas azacitidine was not (adjusted odds ratio 1.08, 95% conﬁdence
interval 0.86–1.35, P= 0.49). However, in patients with chromosome 7 abnormalities, a trend toward a better survival was observed
in azacitidine-treated patients (median survival 13.3 (11–18) months) compared with CCT (median survival 8.6 (5–10.4) months,
P= 0.08). In conclusion, our data show that, in spite of a widespread use of azacitidine, there is a lack of improvement in survival
over the years. Identiﬁcation of predicting factors of response and survival is mandatory.
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INTRODUCTION
Myelodysplastic syndromes (MDS) are a group of clonal
hematological disorders affecting mainly elderly people and
characterized by cytopenias, ineffective hematopoiesis and
increased risk of evolution to acute myeloblastic leukemia
(AML).1 The prognosis of individuals with MDS is very hetero-
geneous and accurately estimated by universally accepted
prognostic scoring indexes such as the International prognostic
scoring system (IPSS, R-IPSS WPSS), which are able to segregate
different risk groups in terms of overall survival (OS) and risk
of AML evolution.2–4 Currently, allogeneic hematopoietic cell
transplantation is the only potential curative treatment for MDS
but is applicable only in a minority of the patients, those younger
ﬁtted patients with a suitable donor. Recently, a randomized
clinical trial undertaken in higher-risk MDS patients who
were not eligible for transplantation has shown that the
hypomethylating agent azacitidine is superior to conventional
care treatment, including best supportive care, in terms of
improving OS and delaying evolution to AML.5,6 However,
information regarding the performance of azacitidine on
daily clinical practice is scarce. Further, the survival advantage
of azacitidine over other treatment alternatives for higher-risk
MDS patients outside the scope of clinical trials remains
unknown.
The main aim of this study was to analyze the potential effect of
different treatment alternatives on OS in a large series of higher-
risk (intermediate-2 and high risk by the IPSS) MDS patients
reported during the last decade to the registry of the Spanish
cooperative group on Myelodysplastic Syndromes (GESMD). For
that purpose we compared the outcome of these patients after
treatment with azacitidine, best supportive care and AML-type
intensive chemotherapy.
PATIENTS AND METHODS
Patients
The primary objective of the study was to compare OS between patients
who received azacitidine as front line therapy and patients who received
conventional treatment, including best supportive care and intensive AML
chemotherapy, in patients with higher-risk MDS. Secondary end points
were to examine risk of AML evolution after the different alternatives and
to recognize predictive factors for OS and risk of AML progression. For
these purposes, this retrospective study included all consecutive higher-
risk MDS patients (deﬁned by FAB and WHO morphological criteria and
having an IPSS risk score of 1.5 or more—intermediate-2 and high-risk
groups) with sufﬁcient follow-up data reported to the registry of the
GESMD between 2000 and 2013. Reporting criteria did not change
with time. Patients with therapy-related MDS were included in the
analysis whereas patients receiving an allogeneic hematopoietic cell
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transplantation were excluded. Patient and disease characteristics
recorded included demographic data, such as date of birth and sex, data
at diagnosis, including date of MDS diagnosis, hemoglobin level, white
blood cell leukocytes, neutrophil, and platelet counts, percentage of blasts
in peripheral blood and bone marrow, cytogenetic abnormalities (classiﬁed
as good, intermediate or poor according to the IPSS classiﬁcation), serum
level of lactate dehydrogenase (LDH), FAB and WHO7 morphologic
classiﬁcations, IPSS risk score, type and date of starting treatment, date
of AML progression, date of death and date of last follow-up. All data were
double-checked for data inconsistency. No central morphology review was
attempted. The cytogenetic reports of all cases were centrally reviewed
(Enric Solé and Elisa Luño) to ensure they followed the ISCN 2009
guidelines.8 In keeping with the guidelines of the Declaration of Helsinki
Principles, the study was conducted with the approval of the internal
review board of the GESMD. All patients provided informed consent.
Statistical analysis
Data are shown as median (interquartile range) or count (percentage) for
descriptive statistics. Comparisons of ranks and proportions were done
using Mann–Whitney U-test, χ2-test or Fisher’s exact test as appropriate. OS
was deﬁned as the time from diagnosis to last follow-up or death from any
cause and analyzed using the Kaplan–Meier estimator. Patients who
remained alive were censored at the time of last follow-up. Survival curves
of patients treated with azacitidine or other therapies were compared
using the method proposed by Simon and Makuch,9 with azacitidine
therapy treated as a time-dependent covariate. In order to analyze
differences in OS between treatment groups, a multivariate Cox regression
model was developed. Treatment with azacitidine was included in the
model as a time-dependent covariate. Possible confounders were also
included in the model. Using this model, hazard ratios with their 95%
conﬁdence interval (CI) were computed. In order to minimize the potential
effect of unmeasured or unknown confounders, an instrumental variable
was also used.10 In particular, and similarly to other authors,11 the
percentage of azacitidine prescription by region was used as the
instrumental variable. This variable was included as a predictor in
the assessment of the mortality risk by Cox proportional hazard analysis.
The same analysis was repeated in speciﬁc subgroups such as in patients
with chronic myelomonocytic leukemia (CMML) and in those with 7/del
(7q) chromosomal abnormalities. We also performed a matched paired
comparison of the outcomes of patients receiving azacitidine and intensive
AML chemotherapy. For this subanalysis, patients who received azacitidine
were matched with patients treated with intensive AML-type chemother-
apy according to a propensity score-based approach that estimates the
probability for a particular patient of being treated with chemotherapy.
This propensity to receive chemotherapy was computed after adjustment
to a general linear model that included age, cytogenetics and percentage
of blasts in bone marrow. Seventy-two matched pairs of patients were
identiﬁed using this method and compared.
Evolution to AML was measured from diagnosis to the date of AML
(presence of more than 19% of blasts in bone marrow or peripheral blood).
Patients dying before leukemic evolution were considered as censored at
the time of death. For the analysis of AML transformation, we exclude
cases that progressed into leukemia within 3 months from diagnosis, as
those patients should be considered closer to AML than to MDS. A similar
scheme to the one previously reported for OS was used for analyzing the
subdistribution from diagnosis to AML evolution. Due to the presence of
competing risks, risk of progression to AML was analyzed by cumulative
incidence methodology; thus, for multivariate analysis of this end point,
the Fine and Gray proportional hazards regression method12 was used.
Two sided P-values o0.05 were considered as statistically signiﬁcant in
all analyses. All the statistical studies and graphs were done using R
software (version 3.0.1) with the packages ‘Survival’, ‘cmprsk’ and ‘ggplot2’
(R Foundation for Statistical Computing, Vienna, Austria, available at http://
www.R-project.org/). R code is available on request.
RESULTS
Characteristics of the patients and therapeutic strategies used
A total of 821 patients with higher-risk MDS were included in the
analysis. There were 512 males and 309 females, with a median
age at diagnosis of 75 years (range, 67–80; Table 1). Median
follow-up time was 9 months (range, 3.7–17.7) for the overall
population and 9.4 months (range, 3.1–19.6) for patients alive at
last follow-up. Median OS for the whole cohort of patients was
12.3 (95% CI, 11.4–14.1) months. The corresponding Kaplan–Meier
survival plot is shown in Figure 1a. OS did not improve over time
(Figure 1b), as the slope of the regression line of median OS versus
year of diagnosis was not signiﬁcantly different from 0 (P= 0.16).
From March 2004 to September 2013, 251 patients (31%)
received azacitidine as ﬁrst-line therapy. The number of cases
treated with azacitidine per year and the percentage of treated
patients according to the year of diagnosis are shown in Figure 2a
and b, respectively. The median delay between diagnosis and
onset of azacitidine was 35 days (range, 18–111). Beyond 2009,
66% of the patients receiving azacitidine as ﬁrst-line therapy were
treated within the ﬁrst 2 months after diagnosis (Figure 2c).
Dosing schedule was available in 179 patients (71%). Seventy-six
patients received a standard 7-day dosing, and the remaining 103
were treated with less intensive regimens. There were no
differences in survival between these two dosing schedules
(P= 0.12, Supplementary Figure S1). Data regarding the number of
cycles received was available in 102 patients (41%). Median
number of cycles given was 6 (interquartile range, 3–9). The
remaining 570 patients (69%) received conventional care treat-
ment (CCT), including best supportive care in 468 patients (57%),
high-dose chemotherapy in 81 patients (16%) and other therapies
in 21 patients (4%; lenalidomide in 18, cyclosporine in 2, and anti-
thymocyte globulin in 1). The main characteristics of the patients
according to the treatment received (azacitidine or CCT) are
shown in Table 1. Age, platelets, absolute neutrophil count and
serum LDH level were signiﬁcantly higher in patients treated with
CCT. All other demographic and biological characteristics, and IPSS
risk score were similar in both treatment groups.
Effect of treatment on OS in the whole series
Median OS was 12.2 months (95% CI, 11–14.1) in the CCT group
compared with 13.4 months (95% CI, 11.8–16) in the azacitidine
group (Figure 3a, P= 0.41). The corresponding actuarial probabil-
ities of OS at 2 years were 22% for patients in the azacitidine
group and 29% in the CCT group. In an attempt to avoid potential
biases inherent to the retrospective nature of the study and
reﬂected in the presence of signiﬁcant differences in some
characteristics of the patients between both treatment groups, we
developed a time-dependent Cox regression model to adjust for
confounding covariates. The results of this model are shown in
Table 2. Treatment with azacitidine was not associated with a
statistically signiﬁcant improvement in OS in this model (hazard
ratio, 1.08; 95% CI, 0.86–1.35; P= 0.49; Figure 3b). Variables
showing a signiﬁcant independent effect on OS in multivariable
models were age, IPSS risk category and LDH, although the impact
of the latter was marginal. Inclusion of other covariates in the
model such as year of diagnosis, sex, bone marrow blasts,
cytogenetics or adding and interaction between azacitidine
treatment and IPSS risk score did not modify the results. Again,
the results were similar when patients with CMML or MDS/
myeloproliferative neoplasm or patients who died within 3 months
from diagnosis were excluded from the analysis. Likewise, when
the instrumental variable was added to the model, overall results
were almost identical.
Effect of treatment on OS in different subpopulations of patients
As shown in Figure 3c, OS in the two risk groups deﬁned by the IPSS
did not clearly differ between those who received azacitidine or CCT
(P=0.853 and P=0.364, respectively, for patients belonging to the
intermediate-2 and high-risk groups). In the subgroup of patients
with CMML, the median OS of patients treated with azacitidine was
20.8 months (95% CI, 10–not reached), whereas it was 15.3 months
(95% CI, 7.5–26.2) in those treated with CCT (P=0.9).
Abnormalities in chromosome 7 were present in 145 patients
(17% of the whole cohort), with 66% harboring a complex
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karyotype. Of those, 49 were treated with azacitidine and 96 with
CCT. OS observed in the azacitidine-treated patients was
13.3 months (95% CI, 11–18) and 8.57 months (95% CI, 5–10.4)
in the CCT group (log-rank P= 0.11, Figure 3d). In the time-
dependent Cox model including FAB classiﬁcation, IPSS, instru-
mental variable and LDH, treatment with azacitidine showed a
trend for better OS compared with CCT (hazard ratio 0.57; 95% CI,
0.30–1.07; P= 0.08).
Then we performed, as described in Patients and methods, a
matched pair comparison between 72 patients treated with
chemotherapy and 72 patients treated with azacitidine. General
characteristics of matched patients and their corresponding
survival curves are shown in Supplementary Table S1 and
Supplementary Figures S2A and B. There were no clear differences
in OS between groups (P= 0.81 and P= 0.63, respectively). A
multivariable regression analysis of this subset of patients also
failed to detect any signiﬁcant effect of treatment with azacitidine
in OS (Supplementary Table S2). In another analysis, excluding
patients who received chemotherapy, median OS was 13.4 months
(11.8–16) for azacitidine-treated patients and 12 months (10.6–
14.8) for patients receiving only supportive care (P= 0.55,
Supplementary Figure S3).
Effect of treatment on AML transformation in the overall series
Cumulative incidence of AML transformation is shown in Figure 4.
Twenty-three percent of the CCT-treated patients progressed into
Table 1. General characteristics of the population
First line azacitidine (N=251) Conventional therapy (N= 570) P-value
Gender 0.36
Male 166 (66) 346 (61)
Female 90 (34) 219 (39)
Age (years) 74 (68–78) 75 (67–81) 0.04
Hemoglobin at diagnosis (g/dl) 9.1 (8–10.4) 9.2 (8–10.5) 0.80
Platelet count at diagnosis (×109/l) 70 (37–114) 75 (43–145) 0.03
WBC (×109/l) 2.95 (1.97–4.99) 3.27 (2.18–5.90) 0.09
ANC (×109/l) 1.06 (0.56–2.04) 1.20 (0.67–2.78) 0.04
Bone marrow blasts (%) 13 (9–16) 13 (8–16) 0.56
LDH (U/l) 338 (233–470) 379 (270–516) 0.01
Secondary MDS 0.36
No 215 (86) 503 (88)
Yes 36 (14) 67 (12)
FAB 0.20
Not classiﬁed 7 (3) 8 (2)
RA 12 (5) 48 (8)
RAEB 162 (64) 350 (61)
RAEB-T 40 (16) 82 (14)
RAS 7 (3) 14 (3)
CMML 19 (8) 64 (11)
Other 4 (1) 4 (1)
WHO 0.23
Not classiﬁed 19 (8) 24 (4)
RA 0 5 (1)
RAEB-1 43 (17) 99 (17)
RAEB-2 128 (51) 271 (48)
RAS 1 (0.3) 1 (0)
RCMD 9 (3.3) 34 (6)
RCMD-SA 6 (2) 15 (3)
AML (420% bl) 23 (9) 51 (9)
5q- 1 (0.3) 4 (1)
Unclassiﬁcable 0 2 (0)
MDS/MPN (CMML) 19 (8) 57 (10)
MDS/MPN (no CMML) 2 (1) 7 (1)
Cytogenetics 0.99
Good 99 (39.5) 221 (39)
Intermediate 48 (19) 109 (19)
Poor 103 (41) 233 (41)
Not available 1 (0.5) 7 (1)
IPSS 0.55
1.5 75 (30) 212 (37)
2 94 (37) 192 (34)
2.5 37 (15) 71 (13)
3 40 (16) 81 (14)
3.5 5 (2) 14 (2)
Abbrevaitions: AML, acute myeloblastic leukemia; ANC, absolute neutrophil count; CMML, chronic myelomonocytic leukemia; FAB, French-American-British;
IPSS, International prognostic score system; LDH, lactate dehydrogenase; MDS/MPN, myelodysplastic syndrome/myeloproliferative neoplasms; RA, refractory
anemia; RAEB, refractory anemia with excess of blasts; RAEB-t, refractory anemia with excess of blasts in transformation; RAS, refractory anemia with ring
sideroblasts; RCMD, refractory anemia with multilineage dysplasia; RCMD-SA, refractory anemia with multilineage dysplasia and ring sideroblasts; WBC, white
blood cell leukocytes; WHO, World Health Organization.
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Figure 1. Overall survival. (a) Survival curve of the whole cohort. (b) Median survival according to the year of diagnosis. Size of each data point
is proportional to the number of cases. A regression line with their 95% conﬁdence interval (shaded area) is presented.
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Figure 2. Treatment with azacitidine. (a) Number of treatments per year. (b) Percentage of patients who are treated with azacitidine as ﬁrst-line
therapy according to the year of diagnosis. (c) Delay between diagnosis of high-risk myelodysplastic syndrome and the onset of azacitidine
treatment. Sample was split according to the year of diagnosis (before or after 2009).
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AML compared with 26% of the azacitidine-treated patients
(P= 0.42). In the multivariable model with competitive risks, AML
transformation was not signiﬁcantly associated with the type of
treatment received (hazard ratio, 1.14; 95% CI, 0.85–1.56; P= 0.38).
The low number of events precluded to analyze the impact of
treatment on AML progression in speciﬁc subsets of patients.
DISCUSSION
In this work we studied the changes in the therapies and
outcomes over a 14-year period in a series of 821 patients with
higher-risk MDS included in the registry of the GESMD. As
expected, our data show that the use of azacitidine as ﬁrst-line
therapy in higher-risk MDS has experienced a fourfold increase in
recent years, largely due to the publication of the results of two
large randomized clinical trials5,6 showing azacitidine to be more
effective than conventional treatment and demonstrating in one
of them a clear survival beneﬁt in patients with higher-risk MDS
(AZA-MDS-001 trial).5 However, in sharp contrast with the results
of these randomized multicenter trials comparing azacitidine to
conventional CCT in patients with higher-risk MDS, we were
unable to show in an unselected population of patients a
signiﬁcant advantage for azacitidine-treated patients in terms of
both OS and AML-free survival. Noteworthy, OS in CCT-treated
patients (median OS, 12.3 months) was similar to the one
observed in the AZA-MDS-001 clinical trial (median OS, 15 months)
whereas OS in azacitidine-treated patients was markedly shorter
than in that study (median OS, 13.1 and 24.5 months, respec-
tively). Further, OS for azacitidine-treated patients in the current
series was closely similar to the one reported by Itzykson et al.13
(median OS, 13.5 months) in 282 higher-risk MDS patients
receiving azacitidine in a patient-named compassionate program
(ATU program). This lack of signiﬁcant beneﬁt for azacitidine-
treated patients remained in multivariable analysis and after
excluding patients with CMML. Additionally, by using a propensity
score technique, a matched pair comparison between azacitidine-
and AML-type chemotherapy-treated patients also failed to reveal
clear differences in their outcomes. Finally, in line with the lack of
survival advantage observed for azacitidine-treated patients, there
were no signiﬁcant changes in the OS of patients with higher-risk
MDS throughout the 2000–2013 period analyzed.
Several factors could potentially explain the apparent discre-
pancies between the results of this retrospective comparative
study and the AZA-MDS-001 clinical trial. First, the incidence of
poor-risk cytogenetics according to IPSS was higher in this report
than in AZA-MDS-001 trial (40% vs 28%, respectively). Further,
most of the chromosome 7 abnormalities were found in the
context of a complex karyotype. Whereas it has been shown that
the beneﬁcial effect of azacitidine is more pronounced in MDS
with chromosome 7 abnormalities,5 its advantage in patients with
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Figure 3. Impact of azacitidine on survival. (a) Survival curves in patients treated with conventional therapy or azacitidine (as ﬁrst-line therapy).
(b) Estimated survival curves according to the Cox regression model, after adjustment by age, IPSS, LDH levels at diagnosis, FAB classiﬁcation
and leukocyte count at diagnosis. There were no signiﬁcant differences between azacitidine and conventional treatment. (c) Survival curves
according to the treatment and the IPSS. (d) Impact of azacitidine on survival in the subgroup of patients with chromosome 7 abnormalities.
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complex karyotype is less clear.13 Yet, azacitidine-treated patients
harboring a -7/del(7q) cytogenetic abnormality showed in our
study a trend to a better OS compared with those in the CCT
group. Another factor that could have affected inﬂuenced the
results is the inclusion in this report, as in the ATU program,13 of
patients with therapy-related MDS (14% in the current series). This
subset of patients has a grim outcome14 and also responds poorly
to azacitidine.15 Third, the median number of cycles of azacitidine
administered in this report (information available in 41% of the
patients) was inferior to the one reported in the randomized AZA-
MDS-0015 clinical trial (6 vs 9), but similar to that reported in the
AZA-AML-001 trial16 and in the ATU program. Whether the lower
than expected number of cycles of azacitidine administered in the
current series in comparison with AZA-MDS-001 clinical trial was
due to more advanced age (median, 74 vs 69 years), presence of
comorbidities or differences in clinical practice is difﬁcult to
ascertain. In spite of these uncertainties, the lack of signiﬁcance of
the instrumental variable allows us to discard a clear inﬂuence of
these or other hidden variables in our the results.
The main strength of this study is the use of a nationwide,
unselected population of higher-risk MDS patients and reﬂecting
clinical daily practice. In fact, our MDS population seems to be
quite representative of these disorders. Their main characteristics
were similar to those observed in other large epidemiological
studies recently published17–20 and the prognostic factors of
outcome isolated in multivariable models, such as age,21 IPSS
score2 and LDH,22 were those expected in MDS patients.
Additionally, the robustness of our ﬁndings is also supported by
the fact that we could not ﬁnd a beneﬁcial effect of azacitidine
when patients treated with chemotherapy or speciﬁc subgroups
(CMML, MDS/myeloproliferative neoplasm and early deaths) were
excluded from the analysis.
In conclusion, our data show that the outcome of patients with
higher-risk MDS has not improved in recent years. Moreover, the
use of azacitidine in this unselected population did not translate
into better outcomes. The reasons for our ﬁndings are unclear and
we cannot exclude that treatment with azacitidine was beneﬁcial
in speciﬁc subgroups of patients. Obviously, the results of this
study require conﬁrmation by other studies, especially coming
from registries in larger populations of patients. Furthermore,
these results illustrate the urgent need of both identifying the
clinical and biological variables related to response to azacitidine
and also addressing the management, efﬁcacy and toxicity of new
agents after regulatory approval and outside clinical trials.
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